Background & aims: We aimed to identify subgroups of patients with unresectable hepatocellular carcinoma (HCC) using a non a priori, data-driven machine learning approach to uncover subgroups with distinct profiles across a range of clinical and tumor-related endpoints. Methods: This international study across 12 centers included patients with unresectable HCC receiving first-line atezolizumab/bevacizumab. Baseline clinical, biological, and tumor characteristics were collected. Clusters were correlated with clinical and tumor-related outcomes, including RECIST 1.1 response, histology, hepatic decompensation, patterns of progression, overall survival (OS) and progression-free survival (PFS). Results: Among 1399 patients (85% male; 75% cirrhotic; 39% with portal vein invasion [PVI]; 35% with metastasis), divided into derivation (n = 958) and validation (n = 409) cohorts, we identified 3 subgroups: Cluster A (47.5% patients): older age, higher body mass index (BMI), preserved liver function, multiple small tumors; Cluster B (11%): VP1/VP2 PVI, higher hepatitis B virus (HBV), and lower metabolic syndrome; Cluster C (41.2%): moderate liver dysfunction, elevated alpha-fetoprotein, and either VP3/VP4 PVI or high tumor burden. Cluster C had poor tumor differentiation (P = .02) and more macrotrabecular massive subtype (P = .02). Cluster A had longer OS (median not reached) vs Clusters B (18.2 months) and C (14.1 months; P < .0001), lower progression rates (25.1% vs 34.3% and 41.2%; P < .0001), and longer PFS (median 10.93 vs 7.73 and 6.10 months; P < .0001). Clusters correlated with prognosis across Barcelona Clinic Liver Cancer stages, occurrence of early hepatic decompensation and patterns of progression (P < .001). Conclusions: The Atezolizumab-Bevacizumab-Cluster (A-B-C) classification for unresectable HCC identified subgroups with histology, hepatic decompensation, and patterns of progression, and prognostic trajectories, informing hypothesis generation for trial design and patient selection.

The "A-B-C" Classification Reveals Outcome Trajectories in Patients With Hepatocellular Carcinoma Under Atezolizumab/Bevacizumab / Campani, C., Galvanin, C., Shim, J.H., Bouattour, M., Touchefeu, Y., Delhoume, V., Rosmorduc, O., Pascale, A., An, J., Lee, H.C., Regnault, H., Thabut, D., Paradis, V., Calderaro, J., Ziol, M., Beaufrère, A., Sayadi, A., Amaddeo, G., Allaire, M., Olivier-Hourmand, I., et al.. - In: CLINICAL GASTROENTEROLOGY AND HEPATOLOGY. - ISSN 1542-3565. - STAMPA. - 24:(2026), pp. 2191-2203. [10.1016/j.cgh.2025.11.018]

The "A-B-C" Classification Reveals Outcome Trajectories in Patients With Hepatocellular Carcinoma Under Atezolizumab/Bevacizumab

Campani, Claudia;Marra, Fabio;Nault, Jean-Charles
2026

Abstract

Background & aims: We aimed to identify subgroups of patients with unresectable hepatocellular carcinoma (HCC) using a non a priori, data-driven machine learning approach to uncover subgroups with distinct profiles across a range of clinical and tumor-related endpoints. Methods: This international study across 12 centers included patients with unresectable HCC receiving first-line atezolizumab/bevacizumab. Baseline clinical, biological, and tumor characteristics were collected. Clusters were correlated with clinical and tumor-related outcomes, including RECIST 1.1 response, histology, hepatic decompensation, patterns of progression, overall survival (OS) and progression-free survival (PFS). Results: Among 1399 patients (85% male; 75% cirrhotic; 39% with portal vein invasion [PVI]; 35% with metastasis), divided into derivation (n = 958) and validation (n = 409) cohorts, we identified 3 subgroups: Cluster A (47.5% patients): older age, higher body mass index (BMI), preserved liver function, multiple small tumors; Cluster B (11%): VP1/VP2 PVI, higher hepatitis B virus (HBV), and lower metabolic syndrome; Cluster C (41.2%): moderate liver dysfunction, elevated alpha-fetoprotein, and either VP3/VP4 PVI or high tumor burden. Cluster C had poor tumor differentiation (P = .02) and more macrotrabecular massive subtype (P = .02). Cluster A had longer OS (median not reached) vs Clusters B (18.2 months) and C (14.1 months; P < .0001), lower progression rates (25.1% vs 34.3% and 41.2%; P < .0001), and longer PFS (median 10.93 vs 7.73 and 6.10 months; P < .0001). Clusters correlated with prognosis across Barcelona Clinic Liver Cancer stages, occurrence of early hepatic decompensation and patterns of progression (P < .001). Conclusions: The Atezolizumab-Bevacizumab-Cluster (A-B-C) classification for unresectable HCC identified subgroups with histology, hepatic decompensation, and patterns of progression, and prognostic trajectories, informing hypothesis generation for trial design and patient selection.
2026
24
2191
2203
Campani, Claudia; Galvanin, Clelia; Shim, Ju Hyun; Bouattour, Mohamed; Touchefeu, Yann; Delhoume, Victoria; Rosmorduc, Olivier; Pascale, Alina; An, Ji...espandi
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1499311
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 2
  • ???jsp.display-item.citation.isi??? ND
social impact